Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
44 hedge funds and large institutions have $50M invested in Terns Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
19% more funds holding
Funds holding: 37 → 44 (+7)
0.95% more ownership
Funds ownership: 65.67% → 66.63% (+0.95%)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
57% less capital invested
Capital invested by funds: $117M → $50M (-$66.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Antara Capital
New York
|
+$534K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$523K |
| 3 |
Renaissance Technologies
New York
|
+$289K |
| 4 |
Millennium Management
New York
|
+$150K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$150K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.05M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$535K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$390K |
| 4 |
Morgan Stanley
New York
|
-$346K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$140K |
TERN Hedge Fund Activity: Q1 2022 in Review
44 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q1 2022, worth a combined $50M — down 57% from $117M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TERN positions and 2 closed out — a net gain of 7 holders — while 10 added to existing stakes and 14 trimmed.
The largest buyer was Antara Capital, adding an estimated $534K. The largest seller was Fidelity Investments, cutting an estimated $2.05M.
- 44 institutional investors held Terns Pharmaceuticals (TERN) as of Q1 2022, up from 37 in Q4 2021.
- Funds reported $50M of Terns Pharmaceuticals stock for Q1 2022, down 57% quarter-over-quarter.
- 9 funds opened new Terns Pharmaceuticals positions in Q1 2022 and 2 closed out, a net change of +7 holders.
- The largest Terns Pharmaceuticals buyer in Q1 2022 was Antara Capital, an estimated $534K added.
- The largest Terns Pharmaceuticals seller in Q1 2022 was Fidelity Investments, an estimated $2.05M sold.
Based on aggregated 13F filings for Q1 2022.